ArticleThe European respiratory journal2022
Biomarkers to identify
Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Circulating metabolites associated with protection against Mycobacterium tuberculosis infection and inhibition of mycobacterial growth.Communications biology · 2026Article
- Molecular signaling in coinfection: howFrontiers in immunology · 2026Review
- Soluble immune mediators orchestrate protectiveeLife · 2025Article
- HIV and diabetes impairIJTLD open · 2024Article
- Systemic and cerebrospinal fluid biomarkers for tuberculous meningitis identification and treatment monitoring.Microbiology spectrum · 2024Article
- Integrating pathogen- and host-derived blood biomarkers for enhanced tuberculosis diagnosis: a comprehensive review.Frontiers in immunology · 2024Review
- Antigen-specific chemokine profiles as biomarkers for detectingFrontiers in immunology · 2024Article
- Review
- Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection.Tropical medicine and infectious disease · 2023Review
- Evaluation of theFrontiers in cellular and infection microbiology · 2023Article
- Alternative biomarkers of tuberculosis infection in patients with immune-mediated inflammatory diseases.Frontiers in medicine · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
backgroundScreening for tuberculosis (TB) infection often includes QuantiFERON-TB Gold Plus (QFT) testing. Previous studies showed that two-thirds of patients with negative QFT results just below the cut-off, so-called borderline test results, nevertheless had other evidence of TB infection. This study aimed to identify a biomarker profile by which borderline QFT results due to TB infection can be distinguished from random test variation.
methodsQFT supernatants of patients with a borderline (≥0.15 and <0.35 IU·mL
conclusionsThis study was able to classify borderline QFT results as likely infection-related or random. These findings support additional laboratory testing for either IP-10 or MIG following a borderline QFT result for individuals at increased risk of reactivation TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.